2022
Propensity-Matched 1-Year Outcomes Following Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients
Deeb GM, Reardon MJ, Ramlawi B, Yakubov SJ, Chetcuti SJ, Kleiman NS, Mangi AA, Zahr F, Song HK, Gada H, Mumtaz M, Heiser J, Merhi W, Murrah CP, Noel T, Kirshner M, Byrne T, Ito S, Huang J, Forrest JK. Propensity-Matched 1-Year Outcomes Following Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients. JACC Cardiovascular Interventions 2022, 15: 511-522. PMID: 35272776, DOI: 10.1016/j.jcin.2021.10.027.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementAortic stenosisTricuspid patientsOutcomes Following Transcatheter Aortic Valve ReplacementEvolut Low Risk trialLow surgical risk patientsIndependent clinical events committeeBicuspid aortic stenosisLow-risk trialsSurgical risk patientsTricuspid aortic stenosisPropensity-matched groupsSerious adverse eventsClinical events committeeIndependent core laboratoryBicuspid aortic valveEffective orifice areaTricuspid groupCause mortalityPrimary endpointTAVR patientsAdverse eventsRisk patients
2018
TCT-184 30-Day Outcomes Following Transcatheter Aortic Valve Replacement with The Evolut PRO Valve in Commercial Use: Report from the STS/ACC TVT Registry
Forrest J, Williams M, Popma J, Reardon M. TCT-184 30-Day Outcomes Following Transcatheter Aortic Valve Replacement with The Evolut PRO Valve in Commercial Use: Report from the STS/ACC TVT Registry. Journal Of The American College Of Cardiology 2018, 72: b78. DOI: 10.1016/j.jacc.2018.08.1299.Peer-Reviewed Original ResearchOutcomes Following Transcatheter Aortic Valve ReplacementSTS/ACC TVT RegistryTranscatheter aortic valve replacementEvolut PRO valveAortic valve replacementTVT RegistryValve replacementRegistry